Cerebroprotection for Acute Ischemic Stroke: Looking Ahead.

Area of Science:

• Neurology
• Translational Medicine
• Pharmacology

Background:

• Ischemic stroke treatment development has a history of failures in translating mechanistic knowledge into effective therapies.
• Previous efforts focused on single-target agents, often hampered by insufficient preclinical rigor and flawed clinical trial designs.

Purpose of the Study:

• To critically evaluate past failures in ischemic stroke treatment development.
• To propose new definitions, approaches, and strategies for developing effective cerebroprotective therapies.

Main Methods:

• Review of criticisms in preclinical and clinical assessments of stroke treatments.
• Analysis of previous single-mechanism treatment development efforts.
• Discussion of novel approaches including pleiotropic, multi-target agents and improved preclinical models.

Main Results:

• Single-target neuroprotection strategies have been largely unsuccessful due to ambiguity and lack of efficacy.
• Pleiotropic agents acting on multiple mechanisms, such as therapeutic hypothermia and 3K3A-APC, show greater promise.
• Improved rigor in preclinical studies, including diverse animal models and patient-like conditions, is crucial.

Conclusions:

• The term 'neuroprotection' should be replaced with 'cerebral cytoprotection' or 'cerebroprotection' for clarity.
• Future cerebroprotective therapies should focus on multi-target agents and recognize the neurovascular unit's differential vulnerability.
• Renewed commitment to scientific rigor in preclinical and clinical research is essential for successful stroke treatment development.